Mark J Alles - Net Worth and Insider Trading
Mark J Alles Net Worth
The estimated net worth of Mark J Alles is at least $22 Million dollars as of 2024-05-02. Mark J Alles is the CEO, CHAIRMAN OF BOARD of Celgene Corp and owns about 193,372 shares of Celgene Corp (CELG) stock worth over $21 Million. Mark J Alles is the Director of Biomarin Pharmaceutical Inc and owns about 10,905 shares of Biomarin Pharmaceutical Inc (BMRN) stock worth over $908,714. Mark J Alles is also the Director of Turning Point Therapeutics Inc and owns about 2,000 shares of Turning Point Therapeutics Inc (TPTX) stock worth over $152,020. Besides these, Mark J Alles also holds Syros Pharmaceuticals Inc (SYRS) . Details can be seen in Mark J Alles's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mark J Alles has not made any transactions after 2022-10-31 and currently still holds the listed stock(s).
Transaction Summary of Mark J Alles
Mark J Alles Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark J Alles owns 3 companies in total, including Syros Pharmaceuticals Inc (SYRS) , Biomarin Pharmaceutical Inc (BMRN) , and Turning Point Therapeutics Inc (TPTX) .
Click here to see the complete history of Mark J Alles’s form 4 insider trades.
Insider Ownership Summary of Mark J Alles
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| SYRS | Syros Pharmaceuticals Inc | 2020-05-13 | director |
| BMRN | Biomarin Pharmaceutical Inc | 2023-05-23 | director |
| TPTX | Turning Point Therapeutics Inc | 2021-06-21 | director |
Mark J Alles Latest Holdings Summary
Mark J Alles currently owns a total of 4 stocks. Among these stocks, Mark J Alles owns 193,372 shares of Celgene Corp (CELG) as of May 9, 2018, with a value of $21 Million and a weighting of 95.15%. Mark J Alles owns 10,905 shares of Biomarin Pharmaceutical Inc (BMRN) as of October 31, 2022, with a value of $908,714 and a weighting of 4.13%. Mark J Alles also owns 2,000 shares of Turning Point Therapeutics Inc (TPTX) as of June 21, 2021, with a value of $152,020 and a weighting of 0.69%. The other 1 stocks Syros Pharmaceuticals Inc (SYRS) have a combined weighting of 0.02% among all his current holdings.
Latest Holdings of Mark J Alles
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CELG | Celgene Corp | 2018-05-09 | 193,372 | 108.24 | 20,930,585 |
| BMRN | Biomarin Pharmaceutical Inc | 2022-10-31 | 10,905 | 83.33 | 908,714 |
| TPTX | Turning Point Therapeutics Inc | 2021-06-21 | 2,000 | 76.01 | 152,020 |
| SYRS | Syros Pharmaceuticals Inc | 2020-05-13 | 1,000 | 5.44 | 5,440 |
Holding Weightings of Mark J Alles
Mark J Alles Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark J Alles has made a total of 0 transactions in Celgene Corp (CELG) over the past 5 years. The most-recent trade in Celgene Corp is the acquisition of 1,208 shares on May 9, 2018, which cost Mark J Alles around $99,781.
According to the SEC Form 4 filings, Mark J Alles has made a total of 1 transactions in Biomarin Pharmaceutical Inc (BMRN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Biomarin Pharmaceutical Inc is the acquisition of 3,625 shares on October 31, 2022, which cost Mark J Alles around $314,469.
According to the SEC Form 4 filings, Mark J Alles has made a total of 1 transactions in Turning Point Therapeutics Inc (TPTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Turning Point Therapeutics Inc is the acquisition of 2,000 shares on June 21, 2021, which cost Mark J Alles around $162,680.
More details on Mark J Alles's insider transactions can be found in the Insider Trading History of Mark J Alles table.Insider Trading History of Mark J Alles
- 1
Mark J Alles Trading Performance
GuruFocus tracks the stock performance after each of Mark J Alles's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark J Alles is 15.4%. GuruFocus also compares Mark J Alles's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark J Alles within 3 months outperforms 3 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Mark J Alles's insider trading performs compared to the benchmark.
Performance of Mark J Alles
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 1.19 | | | | | |
| Relative Return to S&P 500(%) | -3.9 | | | | | |
Mark J Alles Ownership Network
Mark J Alles Owned Company Details
What does Syros Pharmaceuticals Inc do?
Who are the key executives at Syros Pharmaceuticals Inc?
Mark J Alles is the director of Syros Pharmaceuticals Inc. Other key executives at Syros Pharmaceuticals Inc include Chief Medical Officer David Roth , Chief Scientific Officer Eric R Olson , and Chief Financial Officer Jason Haas .
Syros Pharmaceuticals Inc (SYRS) Insider Trades Summary
Over the past 18 months, Mark J Alles made no insider transaction in Syros Pharmaceuticals Inc (SYRS). Other recent insider transactions involving Syros Pharmaceuticals Inc (SYRS) include a net sale of 30,523 shares made by David Roth , a net purchase of 904,977 shares made by Srinivas Akkaraju , and a net sale of 689 shares made by Eric R Olson .
In summary, during the past 3 months, insiders sold 10,601 shares of Syros Pharmaceuticals Inc (SYRS) in total and bought 0 shares, with a net sale of 10,601 shares. During the past 18 months, 31,212 shares of Syros Pharmaceuticals Inc (SYRS) were sold and 904,977 shares were bought by its insiders, resulting in a net purchase of 873,765 shares.
Syros Pharmaceuticals Inc (SYRS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Syros Pharmaceuticals Inc Insider Transactions
Mark J Alles Mailing Address
Above is the net worth, insider trading, and ownership report for Mark J Alles. You might contact Mark J Alles via mailing address: C/o Celgene Corporation, 86 Morris Avenue, Summit Nj 07901.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
